Detalhe da pesquisa
1.
Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program.
Cardiovasc Diabetol
; 21(1): 127, 2022 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35787704
2.
Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.
Am J Nephrol
; 53(1): 21-31, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35016188
3.
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Eur Heart J
; 42(48): 4891-4901, 2021 12 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34423370
4.
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
Diabetologia
; 64(10): 2147-2158, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34415356
5.
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
Kidney Int
; 99(4): 999-1009, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33316282
6.
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
Diabetes Obes Metab
; 23(7): 1652-1659, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33769679
7.
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial.
J Am Soc Nephrol
; 31(12): 2925-2936, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998938
8.
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
J Am Soc Nephrol
; 31(5): 1128-1139, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32354987
9.
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
Circulation
; 140(9): 739-750, 2019 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31291786
10.
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
Diabetes Obes Metab
; 22(10): 1753-1766, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32436638
11.
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Circulation
; 137(14): 1450-1459, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29133607
12.
Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Pharmacoepidemiol Drug Saf
; 28(12): 1620-1628, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31456304
13.
Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
Diabetes Obes Metab
; 20(11): 2585-2597, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29938883
14.
Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment.
Ann Intern Med
; 174(3): 431-432, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33721528
15.
Botulinum Toxin Therapy of Social Anxiety Disorder: A Case Series.
J Clin Psychopharmacol
; 39(4): 410-412, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31188234
16.
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
BMJ Open Diabetes Res Care
; 11(3)2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311602
17.
Controlled trial of safety and efficacy of bright light therapy vs. negative air ions in patients with bipolar depression.
Psychiatry Res
; 196(1): 57-61, 2012 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-22424890
18.
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS).
Diabetes Care
; 45(8): 1893-1899, 2022 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35724306
19.
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.
J Am Coll Cardiol
; 79(5): 432-444, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35115099
20.
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trial.
Cardiovasc Res
; 118(4): 1103-1114, 2022 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33826709